Difference between revisions of "Myelofibrosis"
Jump to navigation
Jump to search
m |
|||
| Line 21: | Line 21: | ||
|[[Levels_of_Evidence#Evidence|'''Evidence''']] | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
|- | |- | ||
| − | |[http://bloodjournal | + | |[http://www.bloodjournal.org/content/108/4/1158.long Tefferi et al. 2006] |
|<span | |<span | ||
style="background:#EEEE00; | style="background:#EEEE00; | ||
| Line 30: | Line 30: | ||
|- | |- | ||
|} | |} | ||
| − | + | ====Chemotherapy==== | |
*[[Lenalidomide (Revlimid)]] 10 mg PO once per day | *[[Lenalidomide (Revlimid)]] 10 mg PO once per day | ||
===References=== | ===References=== | ||
<!-- no pre-pub disclosed --> | <!-- no pre-pub disclosed --> | ||
| − | # Tefferi A, Cortes J, Verstovsek S, Mesa RA, Thomas D, Lasho TL, Hogan WJ, Litzow MR, Allred JB, Jones D, Byrne C, Zeldis JB, Ketterling RP, McClure RF, Giles F, Kantarjian HM. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood. 2006 Aug 15;108(4):1158-64. Epub 2006 Apr 11. [http://bloodjournal | + | # Tefferi A, Cortes J, Verstovsek S, Mesa RA, Thomas D, Lasho TL, Hogan WJ, Litzow MR, Allred JB, Jones D, Byrne C, Zeldis JB, Ketterling RP, McClure RF, Giles F, Kantarjian HM. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood. 2006 Aug 15;108(4):1158-64. Epub 2006 Apr 11. [http://www.bloodjournal.org/content/108/4/1158.long link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/16609064 PubMed] |
==Placebo {{#subobject:2 |Regimen=1}}== | ==Placebo {{#subobject:2 |Regimen=1}}== | ||
| Line 64: | Line 64: | ||
border-width:2px; | border-width:2px; | ||
border-style:solid;">Might have inferior OS</span> | border-style:solid;">Might have inferior OS</span> | ||
| − | |||
| − | |||
|- | |- | ||
|[http://oncology.jamanetwork.com/article.aspx?articleid=2330618 Pardanani et al. 2015] | |[http://oncology.jamanetwork.com/article.aspx?articleid=2330618 Pardanani et al. 2015] | ||
| Line 88: | Line 86: | ||
===References=== | ===References=== | ||
# Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012 Mar 1;366(9):799-807. [http://www.nejm.org/doi/full/10.1056/NEJMoa1110557 link to original article] [http://www.nejm.org/doi/suppl/10.1056/NEJMoa1110557/suppl_file/nejmoa1110557_appendix.pdf supplementary appendix] [http://www.nejm.org/doi/suppl/10.1056/NEJMoa1110557/suppl_file/nejmoa1110557_protocol.pdf trial protocol] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/22375971 PubMed] | # Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012 Mar 1;366(9):799-807. [http://www.nejm.org/doi/full/10.1056/NEJMoa1110557 link to original article] [http://www.nejm.org/doi/suppl/10.1056/NEJMoa1110557/suppl_file/nejmoa1110557_appendix.pdf supplementary appendix] [http://www.nejm.org/doi/suppl/10.1056/NEJMoa1110557/suppl_file/nejmoa1110557_protocol.pdf trial protocol] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/22375971 PubMed] | ||
| − | ## '''Update:''' Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, Dipersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Sun W, Sandor V, Kantarjian HM. Efficacy, safety and survival with ruxolitinib treatment in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica. 2013 Sep 13. | + | ## '''Update:''' Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, Dipersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Sun W, Sandor V, Kantarjian HM. Efficacy, safety and survival with ruxolitinib treatment in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica. 2013 Dec;98(12):1865-71. Epub 2013 Sep 13. [http://www.haematologica.org/content/98/12/1865.full link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/24038026 PubMed] |
# Pardanani A, Harrison C, Cortes JE, Cervantes F, Mesa RA, Milligan D, Masszi T, Mishchenko E, Jourdan E, Vannucchi AM, Drummond MW, Jurgutis M, Kuliczkowski K, Gheorghita E, Passamonti F, Neumann F, Patki A, Gao G, Tefferi A. Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial. JAMA Oncol. 2015 Aug 1;1(5):643-51. [http://oncology.jamanetwork.com/article.aspx?articleid=2330618 link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/26181658 PubMed] | # Pardanani A, Harrison C, Cortes JE, Cervantes F, Mesa RA, Milligan D, Masszi T, Mishchenko E, Jourdan E, Vannucchi AM, Drummond MW, Jurgutis M, Kuliczkowski K, Gheorghita E, Passamonti F, Neumann F, Patki A, Gao G, Tefferi A. Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial. JAMA Oncol. 2015 Aug 1;1(5):643-51. [http://oncology.jamanetwork.com/article.aspx?articleid=2330618 link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/26181658 PubMed] | ||
| Line 113: | Line 111: | ||
|- | |- | ||
|} | |} | ||
| − | + | ====Chemotherapy==== | |
*[[Pomalidomide (Pomalyst)]] 2 mg PO once per day | *[[Pomalidomide (Pomalyst)]] 2 mg PO once per day | ||
| Line 132: | Line 130: | ||
|- | |- | ||
|} | |} | ||
| − | + | ====Chemotherapy==== | |
*[[Pomalidomide (Pomalyst)]] 0.5 mg PO once per day, escalation up to 2 mg PO once per day allowed after first six cycles | *[[Pomalidomide (Pomalyst)]] 0.5 mg PO once per day, escalation up to 2 mg PO once per day allowed after first six cycles | ||
| Line 164: | Line 162: | ||
|- | |- | ||
|} | |} | ||
| − | + | ====Chemotherapy==== | |
*[[Pomalidomide (Pomalyst)]] 2 mg PO once per day | *[[Pomalidomide (Pomalyst)]] 2 mg PO once per day | ||
*[[Prednisone (Sterapred)]] as follows: | *[[Prednisone (Sterapred)]] as follows: | ||
| Line 189: | Line 187: | ||
|- | |- | ||
|} | |} | ||
| − | + | ====Chemotherapy==== | |
*[[Pomalidomide (Pomalyst)]] 0.5 mg PO once per day | *[[Pomalidomide (Pomalyst)]] 0.5 mg PO once per day | ||
*[[Prednisone (Sterapred)]] as follows: | *[[Prednisone (Sterapred)]] as follows: | ||
| Line 224: | Line 222: | ||
|- | |- | ||
|} | |} | ||
| − | + | ====Chemotherapy==== | |
*[[Prednisone (Sterapred)]] as follows: | *[[Prednisone (Sterapred)]] as follows: | ||
**Cycle 1: 30 mg PO once per day | **Cycle 1: 30 mg PO once per day | ||
| Line 230: | Line 228: | ||
**Cycle 3: 15 mg PO every other day | **Cycle 3: 15 mg PO every other day | ||
| − | '''28-day cycle | + | '''28-day cycle for 3 cycles''' |
===References=== | ===References=== | ||
| Line 259: | Line 257: | ||
border-style:solid;">Phase II</span> | border-style:solid;">Phase II</span> | ||
| | | | ||
| − | |||
| − | |||
|- | |- | ||
|[http://www.nejm.org/doi/full/10.1056/NEJMoa1110557 Verstovsek et al. 2012 (COMFORT-I)] | |[http://www.nejm.org/doi/full/10.1056/NEJMoa1110557 Verstovsek et al. 2012 (COMFORT-I)] | ||
| Line 276: | Line 272: | ||
border-width:2px; | border-width:2px; | ||
border-style:solid;">Might have superior OS</span> | border-style:solid;">Might have superior OS</span> | ||
| − | |||
| − | |||
|- | |- | ||
|[http://www.nejm.org/doi/full/10.1056/NEJMoa1110556 Harrison et al. 2012 (COMFORT-II)] | |[http://www.nejm.org/doi/full/10.1056/NEJMoa1110556 Harrison et al. 2012 (COMFORT-II)] | ||
| Line 293: | Line 287: | ||
border-width:2px; | border-width:2px; | ||
border-style:solid;">Seems to have superior OS</span> | border-style:solid;">Seems to have superior OS</span> | ||
| − | |||
| − | |||
|- | |- | ||
|[http://onlinelibrary.wiley.com/doi/10.1111/bjh.13379/full Mead et al. 2015 (ROBUST)] | |[http://onlinelibrary.wiley.com/doi/10.1111/bjh.13379/full Mead et al. 2015 (ROBUST)] | ||
| Line 308: | Line 300: | ||
|} | |} | ||
| − | ''Patients in COMFORT-II who received "best available therapy" generally received no active treatment, [[Hydroxyurea (Hydrea)]], or [[:Category:Steroids|glucocorticoids]].'' | + | ''Patients in '''COMFORT-II''' who received "best available therapy" generally received no active treatment, [[Hydroxyurea (Hydrea)]], or [[:Category:Steroids|glucocorticoids]].'' |
| − | + | ====Chemotherapy==== | |
*[[Ruxolitinib (Jakafi)]] 10 to 25 mg PO twice per day | *[[Ruxolitinib (Jakafi)]] 10 to 25 mg PO twice per day | ||
| Line 317: | Line 309: | ||
# Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, Vaddi K, Levy R, Tefferi A. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010 Sep 16;363(12):1117-27. [http://www.nejm.org/doi/full/10.1056/NEJMoa1002028 link to original article] [http://www.nejm.org/doi/suppl/10.1056/NEJMoa1002028/suppl_file/nejmoa1002028_appendix.pdf supplementary appendix] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/20843246 PubMed] | # Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, Vaddi K, Levy R, Tefferi A. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010 Sep 16;363(12):1117-27. [http://www.nejm.org/doi/full/10.1056/NEJMoa1002028 link to original article] [http://www.nejm.org/doi/suppl/10.1056/NEJMoa1002028/suppl_file/nejmoa1002028_appendix.pdf supplementary appendix] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/20843246 PubMed] | ||
# Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012 Mar 1;366(9):799-807. [http://www.nejm.org/doi/full/10.1056/NEJMoa1110557 link to original article] [http://www.nejm.org/doi/suppl/10.1056/NEJMoa1110557/suppl_file/nejmoa1110557_appendix.pdf supplementary appendix] [http://www.nejm.org/doi/suppl/10.1056/NEJMoa1110557/suppl_file/nejmoa1110557_protocol.pdf trial protocol] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/22375971 PubMed] | # Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012 Mar 1;366(9):799-807. [http://www.nejm.org/doi/full/10.1056/NEJMoa1110557 link to original article] [http://www.nejm.org/doi/suppl/10.1056/NEJMoa1110557/suppl_file/nejmoa1110557_appendix.pdf supplementary appendix] [http://www.nejm.org/doi/suppl/10.1056/NEJMoa1110557/suppl_file/nejmoa1110557_protocol.pdf trial protocol] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/22375971 PubMed] | ||
| − | ## '''Update:''' Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, Dipersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Sun W, Sandor V, Kantarjian HM. Efficacy, safety and survival with ruxolitinib treatment in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica. 2013 Sep 13. | + | ## '''Update:''' Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, Dipersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Sun W, Sandor V, Kantarjian HM. Efficacy, safety and survival with ruxolitinib treatment in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica. 2013 Dec;98(12):1865-71. Epub 2013 Sep 13. [http://www.haematologica.org/content/98/12/1865.full link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/24038026 PubMed] |
| − | ## '''Update:''' Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner EO, Lyons RM, Raza A, Vaddi K, Sun W, Peng W, Sandor V, Kantarjian H. Three-year efficacy, overall survival, and safety of ruxolitinib therapy in patients with myelofibrosis from the COMFORT-I study. Haematologica. 2015 Jan 23. | + | ## '''Update:''' Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner EO, Lyons RM, Raza A, Vaddi K, Sun W, Peng W, Sandor V, Kantarjian H. Three-year efficacy, overall survival, and safety of ruxolitinib therapy in patients with myelofibrosis from the COMFORT-I study. Haematologica. 2015 Apr;100(4):479-88. Epub 2015 Jan 23. [http://www.haematologica.org/content/100/4/479.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/25616577 PubMed] |
# Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, Cervantes F, Vannucchi AM, Barbui T, Barosi G. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012 Mar 1;366(9):787-98. [http://www.nejm.org/doi/full/10.1056/NEJMoa1110556 link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/22375970 PubMed] content property of [http://hemonc.org HemOnc.org] | # Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, Cervantes F, Vannucchi AM, Barbui T, Barosi G. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012 Mar 1;366(9):787-98. [http://www.nejm.org/doi/full/10.1056/NEJMoa1110556 link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/22375970 PubMed] content property of [http://hemonc.org HemOnc.org] | ||
| − | ## '''Update:''' Cervantes F, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Sirulnik A, Stalbovskaya V, McQuitty M, Hunter DS, Levy RS, Passamonti F, Barbui T, Barosi G, Harrison CN, Knoops L, Gisslinger H. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013 Oct 30. | + | ## '''Update:''' Cervantes F, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Sirulnik A, Stalbovskaya V, McQuitty M, Hunter DS, Levy RS, Passamonti F, Barbui T, Barosi G, Harrison CN, Knoops L, Gisslinger H. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013 Dec 12;122(25):4047-53. Epub 2013 Oct 30. [http://www.bloodjournal.org/content/122/25/4047.full link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/24174625 PubMed] |
| − | # Mead AJ, Milojkovic D, Knapper S, Garg M, Chacko J, Farquharson M, Yin J, Ali S, Clark RE, Andrews C, Ktiouet Dawson M, Harrison C. Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial. Br J Haematol. 2015 Mar 30. | + | ## '''Update:''' Harrison CN, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Gisslinger H, Knoops L, Cervantes F, Jones MM, Sun K, McQuitty M, Stalbovskaya V, Gopalakrishna P, Barbui T. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016 Aug;30(8):1701-7. Epub 2016 May 23. [http://www.nature.com/leu/journal/v30/n8/full/leu2016148a.html link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/27211272 PubMed] |
| + | # Mead AJ, Milojkovic D, Knapper S, Garg M, Chacko J, Farquharson M, Yin J, Ali S, Clark RE, Andrews C, Ktiouet Dawson M, Harrison C. Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial. Br J Haematol. 2015 Jul;170(1):29-39. Epub 2015 Mar 30. [http://onlinelibrary.wiley.com/doi/10.1111/bjh.13379/full link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/25824940 PubMed] | ||
Revision as of 21:26, 16 August 2016
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.
9 regimens on this page
11 variants on this page
|
Lenalidomide (Revlimid)
| back to top |
Regimen
| Study | Evidence |
| Tefferi et al. 2006 | Phase II |
Chemotherapy
- Lenalidomide (Revlimid) 10 mg PO once per day
References
- Tefferi A, Cortes J, Verstovsek S, Mesa RA, Thomas D, Lasho TL, Hogan WJ, Litzow MR, Allred JB, Jones D, Byrne C, Zeldis JB, Ketterling RP, McClure RF, Giles F, Kantarjian HM. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood. 2006 Aug 15;108(4):1158-64. Epub 2006 Apr 11. link to original article contains protocol PubMed
Placebo
| back to top |
Regimen
| Study | Evidence | Comparator | Efficacy |
| Verstovsek et al. 2012 (COMFORT-I) | Phase III | Ruxolitinib | Might have inferior OS |
| Pardanani et al. 2015 | Phase III | Fedratinib | Inferior RR |
No active treatment; included here because it was used as a comparator in one or more randomized controlled trials. Note that although fedratinib had superior efficacy to placebo per Pardanani et al. 2015, it had unacceptable toxicity and is no longer under active development.
References
- Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012 Mar 1;366(9):799-807. link to original article supplementary appendix trial protocol contains verified protocol PubMed
- Update: Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, Dipersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Sun W, Sandor V, Kantarjian HM. Efficacy, safety and survival with ruxolitinib treatment in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica. 2013 Dec;98(12):1865-71. Epub 2013 Sep 13. link to original article PubMed
- Pardanani A, Harrison C, Cortes JE, Cervantes F, Mesa RA, Milligan D, Masszi T, Mishchenko E, Jourdan E, Vannucchi AM, Drummond MW, Jurgutis M, Kuliczkowski K, Gheorghita E, Passamonti F, Neumann F, Patki A, Gao G, Tefferi A. Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial. JAMA Oncol. 2015 Aug 1;1(5):643-51. link to original article PubMed
Pomalidomide (Pomalyst)
| back to top |
Regimen #1
| Study | Evidence | Comparator |
| Tefferi et al. 2009 | Randomized Phase II, >20 in this arm | Pomalidomide (2 mg/d) & Prednisone Pomalidomide (0.5 mg/d) & Prednisone Prednisone |
Chemotherapy
- Pomalidomide (Pomalyst) 2 mg PO once per day
28-day cycles
Regimen #2
| Study | Evidence |
| Begna et al. 2010 | Phase II |
Chemotherapy
- Pomalidomide (Pomalyst) 0.5 mg PO once per day, escalation up to 2 mg PO once per day allowed after first six cycles
28-day cycles
References
- Tefferi A, Verstovsek S, Barosi G, Passamonti F, Roboz GJ, Gisslinger H, Paquette RL, Cervantes F, Rivera CE, Deeg HJ, Thiele J, Kvasnicka HM, Vardiman JW, Zhang Y, Bekele BN, Mesa RA, Gale RP, Kantarjian HM. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol. 2009 Sep 20;27(27):4563-9. Epub 2009 Aug 3. link to original article PubMed
- Begna KH, Mesa RA, Pardanani A, Hogan WJ, Litzow MR, McClure RF, Tefferi A. A phase-2 trial of low-dose pomalidomide in myelofibrosis. Leukemia. 2011 Feb;25(2):301-4. Epub 2010 Nov 5. trial protocol contains verified protocol PubMed
Pomalidomide & Prednisone
| back to top |
Regimen #1
| Study | Evidence | Comparator |
| Tefferi et al. 2009 | Randomized Phase II, <20 in this arm | Pomalidomide Pomalidomide (0.5 mg/d) & Prednisone Prednisone |
Chemotherapy
- Pomalidomide (Pomalyst) 2 mg PO once per day
- Prednisone (Sterapred) as follows:
- Cycle 1: 30 mg PO once per day
- Cycle 2: 15 mg PO once per day
- Cycle 3: 15 mg PO every other day
28-day cycles
Regimen #2
| Study | Evidence | Comparator |
| Tefferi et al. 2009 | Randomized Phase II, >20 in this arm | Pomalidomide Pomalidomide (2 mg/d) & Prednisone Prednisone |
Chemotherapy
- Pomalidomide (Pomalyst) 0.5 mg PO once per day
- Prednisone (Sterapred) as follows:
- Cycle 1: 30 mg PO once per day
- Cycle 2: 15 mg PO once per day
- Cycle 3: 15 mg PO every other day
28-day cycles
References
- Tefferi A, Verstovsek S, Barosi G, Passamonti F, Roboz GJ, Gisslinger H, Paquette RL, Cervantes F, Rivera CE, Deeg HJ, Thiele J, Kvasnicka HM, Vardiman JW, Zhang Y, Bekele BN, Mesa RA, Gale RP, Kantarjian HM. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol. 2009 Sep 20;27(27):4563-9. Epub 2009 Aug 3. link to original article PubMed
Prednisone (Sterapred)
| back to top |
Regimen
| Study | Evidence | Comparator |
| Tefferi et al. 2009 | Randomized Phase II, >20 in this arm | Pomalidomide Pomalidomide (2 mg/d) & Prednisone Pomalidomide (0.5 mg/d) & Prednisone |
Chemotherapy
- Prednisone (Sterapred) as follows:
- Cycle 1: 30 mg PO once per day
- Cycle 2: 15 mg PO once per day
- Cycle 3: 15 mg PO every other day
28-day cycle for 3 cycles
References
- Tefferi A, Verstovsek S, Barosi G, Passamonti F, Roboz GJ, Gisslinger H, Paquette RL, Cervantes F, Rivera CE, Deeg HJ, Thiele J, Kvasnicka HM, Vardiman JW, Zhang Y, Bekele BN, Mesa RA, Gale RP, Kantarjian HM. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol. 2009 Sep 20;27(27):4563-9. Epub 2009 Aug 3. link to original article PubMed
Ruxolitinib (Jakafi)
| back to top |
Regimen
COMFORT: COntrolled MyeloFibrosis Study with ORal JAK Inhibitor Treatment
| Study | Evidence | Comparator | Efficacy |
| Verstovsek et al. 2010 | Phase II | ||
| Verstovsek et al. 2012 (COMFORT-I) | Phase III | Placebo | Might have superior OS |
| Harrison et al. 2012 (COMFORT-II) | Phase III | "Best available therapy" | Seems to have superior OS |
| Mead et al. 2015 (ROBUST) | Phase II |
Patients in COMFORT-II who received "best available therapy" generally received no active treatment, Hydroxyurea (Hydrea), or glucocorticoids.
Chemotherapy
- Ruxolitinib (Jakafi) 10 to 25 mg PO twice per day
Given until progression
References
- Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, Vaddi K, Levy R, Tefferi A. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010 Sep 16;363(12):1117-27. link to original article supplementary appendix contains verified protocol PubMed
- Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012 Mar 1;366(9):799-807. link to original article supplementary appendix trial protocol contains verified protocol PubMed
- Update: Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, Dipersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Sun W, Sandor V, Kantarjian HM. Efficacy, safety and survival with ruxolitinib treatment in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica. 2013 Dec;98(12):1865-71. Epub 2013 Sep 13. link to original article PubMed
- Update: Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner EO, Lyons RM, Raza A, Vaddi K, Sun W, Peng W, Sandor V, Kantarjian H. Three-year efficacy, overall survival, and safety of ruxolitinib therapy in patients with myelofibrosis from the COMFORT-I study. Haematologica. 2015 Apr;100(4):479-88. Epub 2015 Jan 23. link to original article PubMed
- Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, Cervantes F, Vannucchi AM, Barbui T, Barosi G. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012 Mar 1;366(9):787-98. link to original article contains verified protocol PubMed content property of HemOnc.org
- Update: Cervantes F, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Sirulnik A, Stalbovskaya V, McQuitty M, Hunter DS, Levy RS, Passamonti F, Barbui T, Barosi G, Harrison CN, Knoops L, Gisslinger H. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013 Dec 12;122(25):4047-53. Epub 2013 Oct 30. link to original article PubMed
- Update: Harrison CN, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Gisslinger H, Knoops L, Cervantes F, Jones MM, Sun K, McQuitty M, Stalbovskaya V, Gopalakrishna P, Barbui T. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016 Aug;30(8):1701-7. Epub 2016 May 23. link to original article PubMed
- Mead AJ, Milojkovic D, Knapper S, Garg M, Chacko J, Farquharson M, Yin J, Ali S, Clark RE, Andrews C, Ktiouet Dawson M, Harrison C. Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial. Br J Haematol. 2015 Jul;170(1):29-39. Epub 2015 Mar 30. link to original article contains protocol PubMed